Boston Common Asset Management LLC Has $16.02 Million Stock Holdings in Roche Holding AG $RHHBY

Boston Common Asset Management LLC decreased its stake in shares of Roche Holding AG (OTCMKTS:RHHBY) by 5.0% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 322,354 shares of the company’s stock after selling 17,039 shares during the quarter. Roche comprises 1.0% of Boston Common Asset Management LLC’s investment portfolio, making the stock its 28th biggest position. Boston Common Asset Management LLC’s holdings in Roche were worth $16,024,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. S&CO Inc. lifted its position in Roche by 163.0% during the first quarter. S&CO Inc. now owns 140,551 shares of the company’s stock worth $6,880,000 after acquiring an additional 87,107 shares during the last quarter. Enterprise Financial Services Corp grew its position in shares of Roche by 6.6% in the first quarter. Enterprise Financial Services Corp now owns 5,576 shares of the company’s stock valued at $277,000 after purchasing an additional 345 shares during the last quarter. Archer Investment Corp grew its position in shares of Roche by 7.7% in the first quarter. Archer Investment Corp now owns 5,598 shares of the company’s stock valued at $278,000 after purchasing an additional 398 shares during the last quarter. Pinnacle Wealth Management Advisory Group LLC bought a new position in shares of Roche during the first quarter worth approximately $208,000. Finally, OLD National Bancorp IN increased its stake in shares of Roche by 0.7% during the first quarter. OLD National Bancorp IN now owns 257,854 shares of the company’s stock worth $12,623,000 after purchasing an additional 1,732 shares during the period.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on RHHBY shares. Morgan Stanley upgraded Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 price target for the company in a research note on Friday, April 24th. Zacks Research cut Roche from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. HSBC downgraded Roche from a “buy” rating to a “hold” rating in a report on Monday, July 6th. Finally, Argus raised shares of Roche from a “hold” rating to a “buy” rating in a research report on Monday, April 6th. Four analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $51.50.

Roche Stock Performance

Shares of OTCMKTS:RHHBY opened at $51.60 on Monday. Roche Holding AG has a 12-month low of $37.51 and a 12-month high of $60.85. The company’s 50 day moving average price is $51.35 and its two-hundred day moving average price is $52.68. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.12 and a current ratio of 1.38.

Roche Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.